Overall impact
C (53)

Commentary

Penumbra is an average overall performer. With a 'C' rating of 52.8 for overall impact (47th percentile compared to all companies), Penumbra ranks 83rd out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 79 others, and ahead of AtriCure, Orthopediatrics, Integra Lifesciences and 17 others. On top material causes for Penumbra's industry (Healthcare Equipment), Penumbra performs poorly in Humane Treatment of Animals (18.7 score), Decent, Safe Work Opportunities (37.0), Conflict Free Mineral Production (39.2) and 1 other cause where it received a 'D' or 'F' score. Penumbra did not receive an 'A' rating on any cause.
Impact
Cause PEN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2004
Employees
4,700
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ca, United States
Share classes
PEN
Mission
To provide a range of high quality services and activities that improves the mental health and wellbeing of people in Scotland. To achieve this we shall seek creative and innovative solutions and work in partnership with agencies and people who share our vision.
Description
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands. The Penumbra System is an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands. Additionally, the company offers neuro embolization coiling systems that include the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as the Ruby Coil System consisting of detachable coils for peripheral applications; the Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; the POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Material causes
Ethos considers the following causes material for Penumbra, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.